종목/CMPS
C
컴퍼스 패스웨이스(ADR)
CMPSNasdaqGS· HealthcareCOMPASS Pathways plc
$14.82
종가· 6. 27.
$2.0B
시가총액
$14.82
6. 27. 종가
시가총액
$2.0B
BEAT5월 13일 (수)장전실제값2026 Q1 실적 발표 결과
EPS 실제
$-0.30
예상 $-0.39
Surprise
+22.2%
매출
$0
발표 직후 반응
—
최근 2분기:
·이번 분기는 Beat, 1연속 Beat 행진
동종업계 비교
Healthcare · 시총 상위기업 정보
섹터Healthcare
산업Medical Care Facilities
대표이사—
상장일9월 18일 (금)
발행주식수134.9M주
직원수156명
회사 소개 보기
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
분기 실적 히스토리
최근 2분기| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 5월 13일 (수) | 2026 Q1 | $-0.39 | $-0.30 | +22.2% | $0 | — |
| 3월 24일 (화) | 2025 Q4 | $-0.40 | $-1.00 | −148.6% | $0 |